Clinical trials: Disease Exacerbation
Cystitis
Study to Evaluate the Efficacy and Safety of XC243 in Patients With Exacerbation of Chronic Cystitis
Multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of XC243 in patients with exacerbation of chronic cystitis.
- Trial name
- NCT06391164
- Testing
- XC243 25 mg, XC243 50 mg, XC243 75 mg
- Where
- 8 sites in Russia
- Volunteers
- 280 people
- Sponsor
- PHARMENTERPRISES LLC
Pulmonary Disease, Chronic Obstructive
Simvastatin Therapy for Moderate and Severe COPD
To determine the effect of daily administration of 40 mgms simvastatin taken for at least 12 months (range 12-36 months) on the frequency of exacerbations of chronic obstructive lung disease (COPD) in patients with moderate to…
- Trial name
- STATCOPE (NCT01061671)
- Testing
- simvastatin
- Where
- 51 sites in United States, Canada
- Volunteers
- 885 people
- Sponsor
- University of Minnesota
Chronic Obstructive Pulmonary Disease
Comparison of a Serum PRO-CT Guided Treatment and the Recommended Antibiotic Treatment for COPD
Exacerbations of chronic obstructive pulmonary disease (COPD) are the first cause of admission to Pulmonary Department in Italy and worldwide.
- Trial name
- NCT01125098
- Testing
- PRO-CT values
- Where
- Italy
- Volunteers
- 183 people
- Sponsor
- University of Modena and Reggio Emilia
Diaphragm Electrical Activity, COPD (Chronic Obstructive Pulmonary Disease)
Effect of Electrical Diaphragmatic Stimulation on Chronic Obstructive Pulmonary Disease
Respiratory muscle dysfunction is a common consequence of chronic obstructive pulmonary disease (COPD). This technique consists of placing electrodes on the skin at locations near the motor points of the diaphragm, transmitting…
- Trial name
- NCT07020299
- Testing
- Device : Digital electrical muscle stimulator is applied to induce diaphragm contraction.
- Where
- Egypt
- Volunteers
- 128 people
- Sponsor
- Mansoura University Hospital
Bronchiectasis
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14…
- Trial name
- RESPIRE 2 (NCT02106832)
- Testing
- Ciprofloxacin (BAYQ3939) dry powder for inhalation
- Where
- 207 sites in United States, Argentina and 23 more
- Volunteers
- 521 people
- Sponsor
- Bayer
Chronic Obstructive Pulmonary Disease, COPD Exacerbation
Efficacy of Varenicline on Smoking Cessation at the Acute Phase of an Exacerbation of Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease of the bronchi with an increasing prevalence. By 2020, the mortality related to COPD is expected to become the 3rd leading death worldwide.
- Conditions
- Chronic Obstructive Pulmonary Disease, COPD Exacerbation, Smoking
- Trial name
- SAVE (NCT01694732)
- Testing
- Varenicline
- Where
- 13 sites in France
- Volunteers
- 83 people
- Sponsor
- University Hospital, Brest
Pulmonary Disease, Chronic Obstructive
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
The aim of this study is to provide high quality data and give a comprehensive overview of characteristics, clinical features, management and prognosis during exacerbations and stable periods among inpatients with acute…
- Trial name
- NCT05032898
- Volunteers
- 1,500 people
- Sponsor
- China-Japan Friendship Hospital
Chronic Obstructive Pulmonary Disease, Exacerbations
Micro-environment Involvement in Muscle Alteration Induced
Chronic Obstructive Pulmonary Disease (COPD) is characterized by persistent airway obstruction and inflammatory response of the lungs and bronchi.
- Conditions
- Chronic Obstructive Pulmonary Disease, Exacerbations, Skeletal Muscle Atrophy
- Trial name
- MicAMI-BPCO (NCT04448626)
- Where
- France
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
COPD (Chronic Obstructive Pulmonary Disease)
The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD.
- Trial name
- STRIDE (NCT07612878)
- Testing
- Cohort 1: Dupilumab, Cohort 2: usual care only
- Where
- 7 sites in United States
- Volunteers
- 350 people
- Sponsor
- Sanofi
COPD Exacerbation
Hospitalization at Home of Elderly Patients With Exacerbated COPD
Aim of the study was to evaluate the efficacy of hospital-at-home treatment compared with inpatient care in selected elderly patients with acute exacerbation of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00369083
- Testing
- Hospital at home treatment
- Volunteers
- 100 people
- Sponsor
- Azienda Ospedaliera San Giovanni Battista
Cystic Fibrosis
Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis
Cystic fibrosis is an inherited disorder leading to chronic pulmonary inflammation and infection. A majority of people with cystic fibrosis have large quantities of bacteria residing in their lungs.
- Trial name
- PIPE-CF (NCT01694069)
- Testing
- Piperacillin-tazobactam combination product
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- West Virginia University
COPD (Chronic Obstructive Pulmonary Disease)
The Effectiveness of Tele-pulmonary Rehabilitation Program on People With Chronic Obstructive Pulmonary Disease (COPD) After Hospitalization for Acute Exacerbation
Introduction: There are great impacts of chronic obstructive pulmonary disease (COPD) over healthcare and economic systems globally.
- Trial name
- NCT07762157
- Testing
- Tele-pulmonary rehabilitation
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- North District Hospital
Cystic Fibrosis, Respiratory Failure
Non Invasive Ventilation for Acute Exacerbations in Adult CF
Cystic Fibrosis (CF) is a life limiting illness. Median predicted UK survival is 41.4 years (UK CF Registry 2011). The commonest cause of death is respiratory failure.
- Trial name
- NIVinCF (NCT02234401)
- Testing
- Bi level pressure support, Standard Care
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Manchester Metropolitan University
Copd, COPD Exacerbation
Atorvastatin Effect on Reduction of COPD Exacerbations
It is a randomized, multicenter, prospective, double-blind, placebo controlled, interventional clinical trial that will be conducted in Poland, in about 12 Hospital Pulmonary Departments to evaluate the effectiveness of…
- Conditions
- Copd, COPD Exacerbation, Smoking, Gene Expression
- Trial name
- Captain (NCT04789057)
- Testing
- Atorvastatin 40 Mg Oral Tablet
- Where
- Poland
- Volunteers
- 460 people
- Sponsor
- Medical University of Bialystok
COPD
Respiratory Pathogens of Patients With Asthma and COPD Exacerbations
To assess the infective etiologies by quantitative polymerase chain reaction (qPCR) of acute exacerbation of COPD and asthma who required hospitalization.
- Trial name
- NCT02866357
- Testing
- No intervention
- Where
- Hong Kong
- Volunteers
- 1,000 people
- Sponsor
- Chinese University of Hong Kong
Chronic Obstructive Pulmonary Disease
CareCOPD - COPD Home Monitoring Study
This is a pilot study to demonstrate early validation of objective home-monitoring of Chronic obstructive pulmonary disease (COPD) patients by combining accurate and relevant patient data of medication and lung function (lung…
- Trial name
- NCT04918095
- Testing
- CareCOPD Platform
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Cognita Labs LLC
Acute Schizophrenia, Schizoaffective Disorder
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.
- Trial name
- REFRESH (NCT01490086)
- Testing
- RP5063, aripiprazole
- Where
- 15 sites in United States, India and 3 more
- Volunteers
- 234 people
- Sponsor
- Reviva Pharmaceuticals
Chronic Obstructive Pulmonary Disease Exacerbation, Pneumonia
Improved Diagnostics, Treatment and Follow-up of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a chronic and often progressive pulmonary disease, where inflammation and recurrent infections are key pathophysiological contibutors in disease progression.
- Conditions
- Chronic Obstructive Pulmonary Disease Exacerbation, Pneumonia, Respiratory Tract Infections
- Trial name
- COPEXNOR (NCT06105814)
- Testing
- Rapid diagnostics
- Volunteers
- 200 people
- Sponsor
- Vestre Viken Hospital Trust
COPD
Exacerbation and Training in Patients With Chronic Obstructive Pulmonary Disease
When patients with chronic obstructive lung disease (COPD) are admitted to the hospital with a severe exacerbation they lose muscle strength. This muscle weakness predisposes these patients to further hospital admissions.
- Trial name
- EXTRA (NCT00877084)
- Testing
- Resistance training, Usual care
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- KU Leuven
Bronchial Asthma
Two Doses of the Intravenous Magnesium Sulfate Versus the Standard Single Dose ,With/ Without the Nebulized Budesonide For the Management of the Severe Asthma Exacerbation in the Emergency Room; A Randomized Controlled Trial.
Many studies have investigated the efficacy and safety of Intravenous magnesium sulfate and inhaled steroids in addition to the standard treatment for patients with severe asthma attacks.
- Trial name
- NCT02455687
- Testing
- Hi-dose iv MgSO4, Nebulized budesonide, Std-dose iv MgSO4
- Where
- Qatar
- Volunteers
- 240 people
- Sponsor
- Hamad Medical Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.